<DOC>
	<DOCNO>NCT00709592</DOCNO>
	<brief_summary>One two different dos thymoglobulin allow bone marrow engraftment minimal Graft-versus-Host Disease allow adequate immune response allow transplant stem cell replace tumor cell .</brief_summary>
	<brief_title>Reduced Intensity Total Body Irradiation + Thymoglobulin Followed Allogeneic PBSCT</brief_title>
	<detailed_description>This randomized phase II trial study well give low dose total-body irradiation ( TBI ) anti-thymocyte globulin follow donor peripheral blood stem cell transplant ( PBSCT ) work treat patient hematologic malignancy . Giving reduced intensity total-body irradiation anti-thymocyte globulin donor peripheral blood stem cell transplant help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving total-body irradiation together antithymocyte globulin transplant may stop happening .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Patients hematological malignancy allogeneic stem cell transplantation indicate include nonHodgkin lymphoma ( NHL ) , multiple myeloma ( MM ) , acute myeloid leukemia ( AML ) , Hodgkin lymphoma ( HD ) , chronic lymphocytic leukemia ( CLL ) , chronic myelogenous leukemia ( CML ) , myelodysplastic syndrome ( MDS ) Patients HLA compatible relate unrelated stem cell donor , willing able serve allogenic HSC donor . Unrelated donor match HLAA , B , C DRB1 locus . A single locus mismatch tolerate event closely match donor available . Patients age &gt; /=40 &lt; /=70 ECOG performance status &lt; 2 Patients 18 40 year age eligible comorbidities preclude conventional allogeneic transplantation full intensity myeloablative conditioning Adequate cardiac , pulmonary , renal hepatic function transplant Negative serology HIV Negative serum pregnancy test Patients receive therapeutic radiation localize field eligible , provide critical structure tolerance dos exceed Patients prior myeloablative autologous transplant eligible Evidence uncontrolled viral , fungal , bacterial infection Evidence active meningeal CNS disease Prior therapy rabbit ATG , prior treatment equine ATG allow 3 month ago Breast feed mother exclude</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>total body irradiation</keyword>
	<keyword>Allogeneic Peripheral Blood Stem Cell Transplantation</keyword>
	<keyword>thymoglobulin</keyword>
</DOC>